Abstract 115P
Background
Trifluridine/tipiracil (lonsurf) and regorafenib are standard of treatment in patients with chemo-refractory metastatic colorectal cancer (mCRC). Our study aimed to investigate the impact of sidedness on survival in patients with mCRC treated with lonsurf or regorafenib.
Methods
Patients who were diagnosed with mCRC and treated with lonsurf or regorafenib between 2015 and 2022 were retrospectively identified from Taiwan National Health Insurance Research Database and Taiwan Cancer Registry. Propensity score matching was used to reduce the selection bias. The oncologic outcomes were presented with time to treatment failure (TTF) and overall survival (OS).
Results
A total of 4665 patients were identified. After matching, 752 patients were analyzed for outcomes comparison, including 376 patients in each group. In general, median TTF and OS were 1.9 months versus 2.0 months (p = 0.701)and 9.1 months versus 7.0 months (p = 0.008) in lonsurf and regorafenib, respectively. Patients were stratified by sidedness, including 297 left side mCRC in each group and 79 right side mCRC in each group. For patients with left side colon, median TTF and OS were 1.9 months versus 2.0 months (p = 0.178) and 10.2 months versus 7.8 months (p = 0.006) in lonsurf and regorafenib, respectively, while for patients with right side colon, median TTF and OS were 1.8 months versus 1.8 months (p = 0.390) and 7.8 months versus 6.0 months (p = 0.011) in lonsurf and regorafenib, respectively.
Conclusions
Lonsurf provided a longer survival over regorafenib in mCRC patients regardless of sidedness of primary tumor location.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract